Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : INCY crawled time : 13:30 save search
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)
Published: 2023-11-22 (Crawled : 13:30) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.74%
H: 0.71%
C: 0.71%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.56%
H: 1.06%
C: -0.24%
drug medical application therapeutics china
Incyte to Present at Upcoming Investor Conferences - October 18, 2023
Published: 2023-10-18 (Crawled : 13:30) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.23%
H: 1.1%
C: -0.42%
Incyte to Report Third Quarter Financial Results - October 10, 2023
Published: 2023-10-10 (Crawled : 13:30) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.48%
H: 1.39%
C: 0.51%
report financial results
Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo
Published: 2022-03-14 (Crawled : 13:30) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.3%
H: 0.85%
C: -2.08%
new drug treatment fda application ces drug
Clinical Catch-Up: Covaxin, Celyad Hold, CRISPR's Next Step
Published: 2022-03-07 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 7.22%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 2.08%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 1.56%
H: 0.0%
C: 0.0%
DRRX | $0.9019 -0.89% -0.9% 110K
|
Health Technology
|
| O: -1.84%
H: 1.67%
C: -7.94%
xin crispr cel
Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer
Published: 2022-03-01 (Crawled : 13:30) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
phase 2 trial therapeutics therapy cancer pancreatic enroll
Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
Published: 2022-01-18 (Crawled : 13:30) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 2.8%
H: 0.78%
C: -0.92%
financial results report results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.